Extended Data Fig. 3
a and b. Representative growth inhibition curves, and corresponding IC50 and AUC values (n = 4, A, n = 7, B, mean ± SD after three days of seeding) from Fig. 2c of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the indicated targeted therapies or chemotherapy drugs (a), FLT3 inhibitors, gilteritinib and sorafenib, or KIT inhibitors, amuvanib and telatinib (b). Av. = Averaged. c. Bioluminescence pictures of three representative mice from Fig. 2i injected with OCI-AML2 cells harboring a non-targeting control or PIK3CG-directed sgRNA. Median bioluminescence is depicted in radiance on days 17, 24, 27 and 31.
